AI Article Synopsis
- A 52-year-old woman with a history of Crohn's disease and arthritis experienced severe hair loss after starting treatment with adalimumab.
- She developed pustular lesions on her palms, soles, and scalp, leading to the discontinuation of adalimumab and a switch to ustekinumab injections.
- After two months of ustekinumab, she sought treatment at a dermatology clinic for her ongoing alopecia, noting she had no personal or family history of psoriasis.
Article Abstract
A 52-year-old woman with a 10-pack-year smoking history presented with serious hair loss. She had a 10-year history of Crohn's disease associated with arthritis, for which she had been taking adalimumab. After 2 months of this treatment, she developed pustular lesions on her palms, soles, and scalp. Her gastroenterologist discontinued adalimumab injections, ordered skin biopsy, and switched her to ustekinumab 90-mg subcutaneous injections every 8 weeks. She then presented to our dermatology clinic, 2 months following the initiation of anti-IL12/23 medications, for her alopecia. She had no personal or family history of psoriasis. (. 2022;20:136-138).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Tumor necrosis factor-alpha (TNF-α) inhibitors are commonly used for management of various autoimmune disorders but can rarely cause isolated cutaneous lupus. This report presents two cases of cutaneous lupus erythematosus (LE) in women aged 38 and 61 after adalimumab treatment for psoriasis highlighting the importance of recognizing these paradoxical reactions for timely management.
View Article and Find Full Text PDFSuccessful Treatment of Adalimumab-Induced Paradoxical Skin Reactions in Pustulotic Arthro-Osteitis With Guselkumab.
Cureus
September 2024
Department of Anatomy, Miyazaki University, Miyazaki, JPN.
Article Synopsis
- * Patients using anti-TNF-α treatments, like adalimumab, often experience paradoxical skin reactions (PSRs), such as rashes and hair loss, necessitating a switch to alternative treatments.
- * Guselkumab, an anti-IL-23 treatment, not only avoids PSRs but also effectively manages PPP/PAO, and it is suggested as a preferable option over adalimumab for patients dealing with these conditions.
Adalimumab induced psoriasis in a Crohn's disease patient: A case report.
J Pak Med Assoc
July 2024
Department of Dermatology, Northern Border University, Arar, Saudi Arabia.
Article Synopsis
- * A 37-year-old male developed palmoplantar psoriasis as an adverse reaction after using adalimumab to treat his Crohn's disease.
- * Despite trying several potent corticosteroids, the psoriasis did not fully clear, leading to a referral to the rheumatologist for a possible change in therapy.
Adalimumab-Induced Erythrodermic Psoriasis Associated with Alopecia in a Patient with Palmoplantar Pustulosis.
Indian J Dermatol
April 2024
From the Department of Dermatology, China-Japan Friendship Hospital, Beijing, China.
Article Synopsis
- Increased use of TNF inhibitors has led to the discovery of more side effects, particularly paradoxical psoriasis.
- Paradoxical psoriasis can manifest in various forms, including psoriasis vulgaris and scalp psoriasis.
- A case is reported of a 44-year-old woman who developed rare erythrodermic psoriasis and alopecia while being treated with adalimumab for palmoplantar pustulosis.
Adalimumab induced exacerbation of psoriasis in patients with combined pemphigus: A case report.
Medicine (Baltimore)
January 2024
Department of Dermatology, Bethune International Peace Hospital, Shijiazhuang, Hebei, China.
Article Synopsis
- Psoriasis is a genetic and immune-related disease, while pemphigus is an autoimmune condition affecting the skin and mucosal tissues; this study reports a rare case where adalimumab exacerbated psoriasis in a pemphigus patient.
- A 43-year-old man with a long history of psoriasis and a recent pemphigus diagnosis experienced a sudden worsening of his skin condition after receiving an adalimumab injection, resulting in increased erythema, scales, and blisters.
- Treatment with methylprednisolone and cyclosporine led to significant improvement in the patient's skin lesions, which healed without recurrence during a six-month follow-up.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!